We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
When our economy recovers, it's a good bet that the biotechnology sector will be one of those sectors leading the way.
Raleigh-based early-stage biomedical device company Micell Technologies has signed an agreement with Maxcor, a subsidiary of Opto Circuits India, to put Micell's drug-delivery technology into Maxcor drug-eluting stents.
Start-up companies in North Carolina that need help bridging early funding gaps en route to government grants or private-equity support have until Friday, Jan. 30 to submit online pre-proposal applications for the next round of grant funding from NC IDEA.
Firms focused on medical devices, green technologies, material sciences or information technology can get grants of up to $50,000 in this seventh application cycle to be offered by the non-profit organization. Since its founding in 2006, NC IDEA has awarded more than $1.2 million to 32 companies.
A jointly developed drought-tolerant corn from BASF Plant Science and Monsanto is being reviewed by the U.S. Food and Drug Administration (FDA) for regulatory clearance, according to the companies.
Monsanto has submitted the product to the FDA and, if approved, the firms expect to have it available to farmers within the next four or five years. The BASF unit's R&D facility is in Research Triangle Park.
North Carolina has opened a trade and investment office in Shanghai, the seventh state Department of Commerce overseas office that promotes business activity. Others are in Hong Kong, Canada, Mexico, Japan, Germany and Korea.
China is North Carolina's second-largest export market, trailing only Canada. Other major markets for Tar Heel goods and services are, in order, Mexico, Japan, Germany and France.
Raleigh-based Arbor Pharmaceuticals has received a Series A venture capital infusion to finance the launch of its third product.
ParagonDx, a genetic and molecular testing diagnostics company based in Morrisville, has started selling a warfarin-sensitivity testing service to doctors' offices.
Warfarin, also known for the brand name Coumadin, is a blood thinner that prevents and treats blood clots. The therapeutic effect for warfarin can vary widely among individuals, depending on their genetic make-up.
Bill Dean, the Director of the Piedmont Triad Research Park has been named Chairman of the newly formed North Carolina Research Parks Network organization. As of January 2009, Bill will chair the Network, a coalition of seven leading science parks located across the state of North Carolina.
Research Triangle Park-based SCYNEXIS has reported positive results from a Phase I clinical trial for its lead oral antiviral drug candidate for treating adults with chronic hepatitis C virus (HCV) infection.
The experimental medicine, dubbed SCY-635, represents a new class of drugs called cyclophilin inhibitors. They're a family of enzymatic proteins related to the more well-known drug cyclosporine that has been used for decades to prevent organ rejection after transplants.
Durham-based Expression Analysis will promote its recent purchase of an Illumina genome analyzer at the International Plant & Animal Genome Conference in San Diego next week, as proof of its entry into the agricultural market.
The 8-year-old provider of genomic services for clinical trials and research intends to use its booth at the show to demonstrate ways agricultural scientists can accelerate their discoveries using Expression Analysis in their biological research.
Research Triangle Park-based Liquidia Technologies and pharmaceutical company Abbott have signed a collaborative agreement to use Liquidia nanotechnology to deliver cancer therapy.
Liquidia, a privately held nanotechnology company co-founded in 2004 on the discoveries of Professor Joseph DeSimone, Ph.D., and colleagues at the University of North Carolina at Chapel Hill, uses a protein particle fabrication method licensed from UNC.
Durham-based Chimerix has started Phase II clinical trials of its oral anti-viral drug candidate, CMX001, after finding positive results in Phase I tests involving 84 healthy volunteers.